Bisolvon Linctus

Bisolvon Linctus

Bromhexine

Inside, adults and children over 10 years — 10-20 ml 3 times a day, children 6-10 years — 5-10 ml 3 times a day, children 2 to 5 years-2.5-5 ml 3 times a day.

hypersensitivity to the components of the drug,

peptic ulcer disease (in the acute stage),

pregnancy,

lactation,

children under 12 years of age (due to the presence of alcohol).

With caution: violation of the motor function of the bronchi and increased volume of secreted secretions (for example, with ciliary dyskinesia syndrome or immobility of the cilia-the risk of stagnation of sputum), bronchial asthma (accidental inhalation of levomentol, eucalyptus and mint oils in the composition of the drug can lead to laryngospasm or can cause an attack of bronchial asthma), reduced kidney function or severe liver disease (should be used with extreme caution. t.e. increasing the intervals between doses of the drug or reducing the dose taken), severe renal failure (possible accumulation of bromhexine metabolites formed in the liver should be taken into account)

The frequency of adverse reactions listed below was determined according to the following criteria: very common (≥10%), common (≥1% to <10%), infrequent (≥0.1% to <1%), rare (≥0.01% to <0.1%), very rare (<0.01%), frequency unknown (cannot be estimated based on available data).

On the part of the immune system: rarely-hypersensitivity reactions, the frequency is unknown-anaphylactic reactions, including anaphylactic shock, angioedema, itching.

From the gastrointestinal tract: infrequently-nausea, abdominal pain, vomiting, diarrhea, rarely-exacerbation of gastric ulcer and duodenal ulcer.

From the skin and subcutaneous tissue: rarely-rash, urticaria, frequency unknown-severe skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis).

From the nervous system: rarely-dizziness, headache.

From the liver and biliary tract: very rarely — an increase in the activity of hepatic transaminases in blood plasma.

General well-being: infrequently-fever, allergic reaction (suffocation).

Life-threatening overdoses when using the drug Bromhexin 8 in humans are unknown.

Symptoms: as a rule, there are no signs of the disease that go beyond the usual side effects.

Treatment for acute overdose: artificial vomiting, gastric lavage, symptomatic therapy.

Bromhexin 8 has a mucolytic (secretolytic), expectorant and weak antitussive effect. Reduces the viscosity of sputum (depolymerizes mucoprotein and mucopolysaccharide fibers, increases the serous component of bronchial secretions), activates the ciliated epithelium, increases the volume and improves the discharge of sputum.

When taken orally, bromhexine is almost completely (99%) absorbed into the gastrointestinal tract within 30 minutes. Bioavailability is 80% due to the effect of the first pass through the liver. Bromhexine in plasma binds to proteins, penetrates through the BBB and the placental barrier. In the liver, bromhexine undergoes demethylation and oxidation, and some of the resulting metabolites (ambroxol) remain active. T_1/2 is 15 h due to slow reverse diffusion from the tissues. C_max the blood level is reached approximately 1 hour after administration. It is excreted by the kidneys. In CRF, the release of bromhexine metabolites is disrupted. With repeated use, bromhexine can accumulate.

• Secretolytics and stimulants of motor function of the respiratory tract

Bromhexin 8 can be prescribed simultaneously with other drugs used in the treatment of bronchopulmonary diseases.

Bromhexin 8 is not prescribed simultaneously with antitussive agents (including those containing codeine), because they can make it difficult to cough up liquefied sputum.

Bromhexin 8 promotes the penetration of antibiotics (amoxicillin, erythromycin, cephalexin, oxytetracycline), sulfonamide drugs into the bronchial secretions in the first 4-5 days of antimicrobial therapy.